Colorectal cancer highlights at ESMO 2024: CheckMate 8HW and BREAKWATER
Автор: VJOncology
Загружено: 2024-10-15
Просмотров: 256
Описание:
Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, gives his highlights in colorectal cancer presented at the European Society for Medical Oncology (ESMO) 2024 Congress, including the outcomes from the CheckMate 8HW study (NCT04008030), which compared first-line nivolumab with ipilimumab to chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC). Dr Modest additionally comments on updates in KRAS G12C colorectal cancer and the BREAKWATER trial (NCT04607421). This interview took place at the ESMO 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
